Business Wire

NTT Group to Launch Smart Cities Initiative with Dell Technologies

Share

NTT Group (NTT, NTT DATA, NTT Communications and Dimension Data) has expanded its partnership with Dell Technologies to include smart city initiatives. The companies will be collaborating on the first smart city proof of concept with the City of Las Vegas as part of the city’s digital transformation.

NTT Group believes smart cities are the natural evolution in public safety that will make full use of next-generation sensors, ultra-high definition cameras and other forward-reaching technologies. Today, video situational awareness is a common practice used by local police and fire agencies to proactively alert public safety stakeholders and first responders to emergencies. However, expanding for future safety measures requires infrastructure and operating models that can analyze and store incoming multimedia data. These requirements are too expensive for most municipalities, limiting the public safety potential of smart city initiatives.

The new NTT Group solution is a secure, distributed platform that will create and deploy micro data centers in proximity to sensors around a city. These micro data centers will use advanced analytics for delivering real-time data to the locations where the data can provide the most value. Predictive and diagnostic analytics at the edge will only send data indicating an incident has occurred or needs investigation back to the core datacenter, minimizing data transport volume and time.

The smart city solution is built on NTT Group’s innovative Cognitive Foundation architecture, which enables remote creation, management and operation of information and communications technology (ICT) resources, from devices and networks to the cloud. It will also combine Dell EMC hyperconverged infrastructure and IoT gateways and VMware vCloud NFV platform hosting predictive analytics applications.

Once the proof of concept is complete, it will allow for proactive data analytics to improve safety. With a robust and scalable infrastructure supporting video situational awareness and sensor data, the city can take advantage of machine learning to improve response times for public safety incidents. After a successful proof of concept in the City of Las Vegas, NTT Group is planning to introduce additional similar initiatives in other U.S. cities.

“Our collaborative approach is unique, and we are delighted to partner with the city of Las Vegas and Dell Technologies to help ensure citizens are safe and critical resources are deployed when needed,” said Jun Sawada, CFO, NTT and CEO, NTT Security. "We’ve brought together NTT Group’s Cognitive Foundation and Dell Technology’s powerful micro data centers to focus on public gathering areas and event venues. This powerful combination facilitates effective and efficient rapid response services,” Sawada said.

“The Innovation District in downtown Las Vegas was designed to be a proving ground for new technologies, and this latest interest by NTT Group and Dell Technologies will continue our efforts to become a smart and connected community,” said Michael Lee Sherwood, Director of Information Technologies, City of Las Vegas. “By leveraging innovative technologies the city will be able to enhance service delivery while helping to keep the public safe and connected.”

“This proof of concept testing with NTT Group strives to improve, modernize and transform the infrastructure in our cities,” said Howard Elias, President, Dell Services, Digital and IT. “We value this joint project with NTT Group to roll out technologically-advanced city-wide initiatives and look forward to helping municipalities worldwide make better use of their resources.”

NTT Group is pleased to introduce the advanced Smart City solution for the digital society era at Dell Technologies World 2018.

About NTT Group
NTT Group is one of the world's largest ICT companies with over 100 billion USD sales and business footprints in 88 countries and regions, inheriting our story of innovation for more than 120 years.

NTT Group accelerates customers' digital agenda with full stack, full life cycle capabilities and world leading research and development, resulting in 88 Fortune 100 companies as our customers.
For more information, visit www.ntt-global.com.

Contact information

Nippon Telegraph and Telephone Corporation
Public Relations Office
E-mail: ntt-cnr-ml@hco.ntt.co.jp

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu